GO:0140522 fusogenic activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140522 fusogenic activity is a molecular function defined as the activity of joining two lipid bilayers to form a single membrane.
• Fusogenic activity is mediated by specialized proteins and peptides that lower the energy barrier for membrane merger, including viral fusion proteins, the micropeptide Myomixer, and FGFRL1.
• Impaired fusogenic activity of Myomixer causes a myopathy resembling Carey-Fineman-Ziter syndrome, linking this molecular function directly to human disease.
• Muscle satellite cell dysfunction, including defects in myoblast fusion, is increasingly recognized in neuromuscular disorders.
• Fusogenic liposomes and nanoparticles exploit this activity for drug and gene delivery, including antimicrobial and osteoarthritis applications.
• Research methods for fusogenic activity include membrane fusion assays, lipid-mixing spectroscopy, live-cell imaging, and CRISPR-based genetic screens.
Description
Fusogenic activity (GO:0140522) is a molecular function that describes the activity of joining two lipid bilayers to form a single membrane. This activity is fundamental to many biological processes, including viral entry, myoblast fusion during muscle development, fertilization, and cell-cell fusion events. The term captures the biochemical capacity of specific proteins or peptides to catalyze membrane merger, a process that is otherwise energetically unfavorable due to repulsive hydration forces between lipid bilayers. Researchers study fusogenic activity to understand how enveloped viruses infect cells, how muscle tissue regenerates, and how membrane fusion can be harnessed for drug delivery. The molecular players that exhibit fusogenic activity are diverse, ranging from viral fusion proteins such as the SARS-CoV-2 spike protein to endogenous micropeptides like Myomixer and receptor tyrosine kinases like FGFRL1. These proteins share the ability to insert into membranes, destabilize lipid packing, and promote the formation of fusion pores. Defects in fusogenic activity are linked to human diseases, including Carey-Fineman-Ziter syndrome-like myopathy and neuromuscular disorders characterized by satellite cell dysfunction. Given its broad relevance, fusogenic activity is a target for both basic research and therapeutic development. Fusogenic liposomes and hybrid nanoparticles are engineered to exploit this activity for enhanced drug delivery, including antimicrobial treatment and cartilage-targeted anti-inflammatory therapy. Understanding the structural and mechanistic basis of fusogenic activity is therefore essential for advancing both cell biology and translational medicine.
fusogenic activity At A Glance
| GO ID | GO:0140522 |
|---|---|
| GO term | fusogenic activity |
| Ontology | molecular_function |
| Synonym | None |
| Definition | The activity of joining two lipid bilayers to form a single membrane. |
| Major function | Catalysis of lipid bilayer merger, enabling membrane fusion events such as viral entry, myoblast fusion, and cell-cell fusion. |
| Related biological processes | Viral entry into host cell, syncytium formation, myoblast fusion, fertilization, and membrane fusion during vesicle trafficking. |
| Representative proteins | Myomixer (MYMX), FGFRL1, viral fusion proteins (e.g., SARS-CoV-2 spike), and fusogenic peptides. |
| Disease relevance | Carey-Fineman-Ziter syndrome-like myopathy, neuromuscular disorders, and viral pathogenesis. |
What Is GO:0140522?
According to the Gene Ontology, fusogenic activity (GO:0140522) is the activity of joining two lipid bilayers to form a single membrane. In other words, it is the molecular function performed by proteins or peptides that catalyze the fusion of two distinct lipid membranes into one continuous bilayer. This activity is distinct from other membrane-related functions such as lipid binding or membrane insertion, because it specifically results in the merger of two separate lipid bilayers. The term is classified under the molecular_function aspect of the Gene Ontology and has no synonyms in the QuickGO database.
Why Is fusogenic activity Important in Cell Biology?
Fusogenic activity is critically important because it underlies fundamental biological processes such as viral infection, muscle development, and tissue regeneration. Impaired fusogenic activity of the micropeptide Myomixer causes a myopathy resembling Carey-Fineman-Ziter syndrome, demonstrating that this molecular function is essential for human muscle health. Additionally, muscle satellite cell dysfunction, which often involves defective myoblast fusion, is increasingly recognized as a contributor to neuromuscular disorders. Beyond physiology, fusogenic activity is exploited in biotechnology for drug delivery, including fusogenic liposomes that enhance antimicrobial activity and hybrid nanoparticles for osteoarthritis treatment. Understanding fusogenic activity therefore has broad implications for infectious disease, regenerative medicine, and targeted therapeutics.
• Mutations impairing the fusogenic activity of Myomixer cause a myopathy resembling Carey-Fineman-Ziter syndrome.
• Muscle satellite cell dysfunction, including defects in myoblast fusion, contributes to neuromuscular disorders.
• Viral fusion proteins, such as the SARS-CoV-2 spike, require fusogenic activity for host cell entry and syncytium formation.
• FGFRL1 fusogenic activity has evolved in vertebrates and plays roles in cell-cell fusion.
• Fusogenic liposomes increase the antimicrobial activity of vancomycin against Staphylococcus aureus biofilms.
• Hybrid nanoparticles engineered with TGF-β1-overexpressed extracellular vesicles and cartilage-targeted liposomes exploit fusogenic activity for osteoarthritis therapy.
• Hepatitis C virus fusion peptides exhibit membranotropic and fusogenic activity, informing antiviral strategies.
• Fusogenic antimicrobial peptides are modulated by lipid shape, providing design principles for new therapeutics.
• Fusogenic activity is essential for fertilization, placental development, and tissue regeneration.
• CRISPR screens can identify genes required for fusogenic activity, accelerating target discovery.
Molecular Mechanism of fusogenic activity
Membrane approach and dehydration
In simple terms: Before two membranes can fuse, they must be brought close together and the water between them removed.
The first step in fusogenic activity involves bringing two lipid bilayers into close apposition. This requires overcoming repulsive hydration forces between the polar head groups of lipids. Fusogenic proteins or peptides facilitate this by inserting amphipathic regions into the membrane, displacing water molecules and reducing the energy barrier for membrane contact. Studies of HCV fusion peptides show that membranotropic sequences can promote membrane perturbation and dehydration, a prerequisite for lipid mixing.
Lipid bilayer destabilization and stalk formation
In simple terms: The membranes then bend and merge at a point, forming a bridge called a stalk.
Once membranes are in close proximity, fusogenic proteins induce local destabilization of lipid packing, leading to the formation of a lipid stalk, a transient structure connecting the outer leaflets of the two bilayers. The shape of lipids influences this process; for example, fusogenic antimicrobial peptides are modulated by lipid shape, with conical lipids promoting negative curvature necessary for stalk formation. FGFRL1 fusogenic activity also depends on specific structural features that enable membrane perturbation.
Fusion pore formation and expansion
In simple terms: A small hole opens between the membranes and expands until the two membranes become one.
Following stalk formation, the inner leaflets merge, creating a fusion pore that connects the two previously separate compartments. This pore then expands, completing the merger of the lipid bilayers into a single continuous membrane. The micropeptide Myomixer is essential for this step in myoblast fusion; impaired Myomixer fusogenic activity leads to defective myotube formation and myopathy. Viral fusion proteins, such as the SARS-CoV-2 spike, also drive fusion pore formation to deliver viral genomes into host cells.
Regulation by accessory proteins and lipid composition
In simple terms: Other proteins and the types of fats in the membrane can turn fusion on or off.
Fusogenic activity is regulated by accessory proteins and the lipid environment. For instance, muscle satellite cell dysfunction in neuromuscular disorders often involves altered expression of fusion-competent proteins. Lipid composition, including the presence of cholesterol and specific phospholipid shapes, modulates the efficiency of fusion. Additionally, fusogenic liposomes can be engineered with specific lipid mixtures to enhance fusion with target membranes, as demonstrated for antimicrobial delivery and cartilage-targeted nanoparticles.
Energetics and structural transitions
In simple terms: Fusion requires energy, and proteins provide it by changing shape.
The merger of lipid bilayers is energetically unfavorable and requires input from fusogenic proteins, which undergo conformational changes to drive the process. For example, viral fusion proteins cycle between prefusion and postfusion states, releasing energy that is used to pull membranes together. Similarly, the fusogenic activity of FGFRL1 is thought to involve structural rearrangements that expose hydrophobic fusion loops. Understanding these energetics is key to designing inhibitors or enhancers of fusion.
Key Genes Involved in GO:0140522 fusogenic activity
The following genes and proteins are directly implicated in fusogenic activity, based on published literature and their roles in membrane fusion events.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYMX (Myomixer) | Micropeptide essential for myoblast fusion; exhibits fusogenic activity | Mutations cause myopathy resembling Carey-Fineman-Ziter syndrome |
| FGFRL1 | Receptor with fusogenic activity involved in cell-cell fusion | Evolutionary studies of fusogenic activity in vertebrates |
| SARS-CoV-2 Spike | Viral fusion protein mediating host cell entry | Target for antiviral research; Omicron lineages show altered fusogenicity |
| HCV E1/E2 | Viral envelope proteins with putative fusion peptides | Model for studying membranotropic and fusogenic peptides |
| Antimicrobial peptides (e.g., LL-37) | Fusogenic peptides that disrupt bacterial membranes | Lipid shape modulates fusogenic activity |
| TGF-β1 | Cytokine delivered via fusogenic nanoparticles | Osteoarthritis therapy using hybrid nanoparticles |
| Vancomycin (with fusogenic liposomes) | Antibiotic delivered via fusogenic liposomes | Enhanced antimicrobial activity against biofilms |
| MYOD1 | Transcription factor regulating myogenesis | Master regulator of myoblast fusion; downstream of Myomixer |
| MYOG | Transcription factor promoting myocyte fusion | Marker of terminal differentiation in muscle |
| NFATC2 | Transcription factor involved in myoblast fusion | Regulates fusion-competent gene expression |
| DYSF | Dysferlin, involved in membrane repair and fusion | Mutations cause muscular dystrophies |
| MYOF | Myoferlin, involved in myoblast fusion | Required for normal muscle development |
| FER1L5 | Ferlin family member involved in fusion | Potential role in myoblast fusion |
| STX4 | Syntaxin 4, SNARE protein | Mediates vesicle fusion; may contribute to myoblast fusion |
| VAMP2 | Vesicle-associated membrane protein 2 | SNARE protein involved in membrane fusion |
| SNAP23 | Synaptosomal-associated protein 23 | SNARE protein implicated in fusion events |
| PLSCR1 | Phospholipid scramblase 1 | May regulate lipid asymmetry during fusion |
| XKR8 | XK-related protein 8 | Phosphatidylserine exposure in fusion-competent cells |
How Is fusogenic activity Regulated?
Fusogenic activity is regulated at multiple levels, including transcriptional control of fusion-competent genes, post-translational modifications, and lipid composition. In muscle, the expression of Myomixer is controlled by myogenic transcription factors such as MYOD1 and MYOG, and its activity is essential for myoblast fusion. Muscle satellite cell dysfunction, which can arise from altered regulation of fusion genes, contributes to neuromuscular disorders. Viral fusogenic activity is regulated by proteolytic cleavage of fusion proteins and conformational changes triggered by receptor binding or low pH. Additionally, lipid shape and membrane composition modulate the efficiency of fusogenic peptides, as shown for antimicrobial peptides.
fusogenic activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYMX | Carey-Fineman-Ziter syndrome-like myopathy | Myomixer knockout mouse or patient-derived iPSC myoblasts |
| FGFRL1 | Cell-cell fusion in development | FGFRL1 knockout cell lines and fusion assays |
| SARS-CoV-2 Spike | COVID-19 pathogenesis and syncytium formation | Pseudovirus entry assays and spike-expressing cells |
| DYSF | Limb-girdle muscular dystrophy | Dysferlin knockout mice and muscle regeneration models |
| PLSCR1 | Defective membrane fusion in immune cells | PLSCR1 knockout cell lines and fusion assays |
Carey-Fineman-Ziter syndrome-like myopathy
Impaired fusogenic activity of the micropeptide Myomixer causes a myopathy resembling Carey-Fineman-Ziter syndrome, characterized by muscle weakness and defective myotube formation. This highlights the critical role of fusogenic activity in muscle development and maintenance.
Neuromuscular disorders and satellite cell dysfunction
Muscle satellite cell dysfunction, including defects in myoblast fusion, is increasingly recognized in neuromuscular disorders. Since satellite cells are essential for muscle regeneration, impaired fusogenic activity can contribute to disease progression.
Viral pathogenesis
Enveloped viruses such as SARS-CoV-2 require fusogenic activity of their spike protein to enter host cells and form syncytia. Evolutionary changes in the spike protein, as seen in Omicron lineages, can alter fusogenic activity and impact viral fitness and antibody evasion.
Infectious diseases and antimicrobial resistance
Fusogenic liposomes can enhance the delivery of antimicrobials such as vancomycin against Staphylococcus aureus biofilms, offering a strategy to overcome resistance. Fusogenic antimicrobial peptides are also being explored as novel antibiotics, with lipid shape influencing their activity.
From fusogenic activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Myomixer abolish myoblast fusion? | MYMX knockout C2C12 myoblasts or mouse model |
| Does a point mutation in the fusion loop of FGFRL1 impair fusogenic activity? | FGFRL1 point-mutation knock-in cell lines |
| Can a tagged version of Myomixer be used to track its localization during fusion? | MYMX knock-in with fluorescent tag in myoblasts |
| Does overexpression of SARS-CoV-2 spike increase syncytium formation? | Spike overexpression in ACE2-expressing cells |
| Which genes are essential for fusogenic activity in a genome-wide screen? | CRISPR knockout library screening in fusion-competent cells |
| Can fusogenic liposomes deliver drugs to biofilms? | In vitro biofilm model with vancomycin-loaded liposomes |
How to Study the fusogenic activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipid-mixing assay | Merger of outer leaflets of lipid bilayers | Quantifying fusogenic activity of peptides or proteins |
| Content-mixing assay | Merger of inner leaflets and formation of fusion pores | Assessing complete membrane fusion |
| Live-cell imaging | Real-time syncytium formation and fusion pore expansion | Visualizing myoblast fusion or viral syncytia |
| CRISPR knockout screen | Genes required for fusogenic activity | Discovery of novel fusion regulators |
| Liposome co-flotation | Binding and insertion of proteins into membranes | Characterizing membrane interactions of fusogenic proteins |
| Circular dichroism | Secondary structure changes upon membrane interaction | Studying conformational transitions of fusogenic peptides |
| Cryo-electron microscopy | High-resolution structure of fusion proteins | Understanding fusion mechanisms |
| Syncytium formation assay | Cell-cell fusion efficiency | Testing viral fusogenicity and antibody neutralization |
Membrane fusion assays
Membrane fusion assays, such as lipid-mixing and content-mixing assays, are used to quantify fusogenic activity. These assays typically employ fluorescent lipids or dyes that change their spectral properties upon membrane merger. For example, studies of HCV fusion peptides used such assays to demonstrate membranotropic and fusogenic activity. Similarly, fusogenic liposomes can be tested for their ability to fuse with bacterial membranes.
Live-cell imaging and syncytium formation
Live-cell imaging allows real-time visualization of membrane fusion events, including the formation of syncytia. Cells expressing viral fusion proteins, such as SARS-CoV-2 spike, can be monitored for syncytium formation using fluorescent reporters. Myoblast fusion can also be tracked by time-lapse microscopy, revealing the dynamics of Myomixer localization and fusion pore expansion.
CRISPR screens for fusion genes
Genome-wide CRISPR knockout screens can identify genes required for fusogenic activity. In such screens, cells are challenged with a fusion-inducing stimulus, and sgRNAs that prevent fusion are enriched. This approach has been used to discover novel fusion regulators in muscle cells and cancer cells. The resulting hits can be validated using targeted knockout or overexpression models.
Biochemical and structural studies
Biochemical assays, such as liposome co-flotation and circular dichroism, can characterize the membrane-interacting properties of fusogenic proteins. Structural techniques, including X-ray crystallography and cryo-electron microscopy, provide atomic-level insights into conformational changes that drive fusion. For instance, structural studies of FGFRL1 have shed light on its fusogenic activity, and lipid shape analysis has informed the design of fusogenic antimicrobial peptides.
How CRISPR Can Be Used to Study GO:0140522 fusogenic activity
Knockout
CRISPR knockout of genes such as MYMX or FGFRL1 can abolish fusogenic activity, providing direct evidence of their function. For example, Myomixer knockout myoblasts fail to fuse, mimicking the myopathy phenotype seen in patients. Knockout models are essential for validating candidate fusion genes identified in screens.
Point Mutation
Point mutations can be introduced to dissect specific residues required for fusogenic activity. For instance, mutating the fusion loop of FGFRL1 or the spike protein of SARS-CoV-2 can impair membrane fusion without affecting protein expression or trafficking. Such models help distinguish between structural and functional roles.
Knock-in
Knock-in of tagged versions of fusion proteins, such as fluorescently labeled Myomixer, allows real-time tracking of protein localization during fusion. This approach can reveal dynamic changes in protein distribution at sites of membrane contact. Knock-in of disease-associated mutations can also model human pathologies.
Overexpression
Overexpression of fusogenic proteins, such as the SARS-CoV-2 spike or FGFRL1, can enhance membrane fusion and syncytium formation. This is useful for studying gain-of-function effects and for producing high-titer pseudoviruses. Overexpression models also facilitate drug screening for fusion inhibitors.
How EDITGENE Supports fusogenic activity Research
Researchers studying fusogenic activity-related genes often need to determine whether a candidate gene is causally involved in membrane fusion, and to dissect the precise residues or domains responsible. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in reporters.
Contact EDITGENE today to design your custom CRISPR model for fusogenic activity research.
Frequently Asked Questions About fusogenic activity
What is fusogenic activity?
Fusogenic activity (GO:0140522) is the activity of joining two lipid bilayers to form a single membrane, a molecular function essential for processes like viral entry and myoblast fusion.
What genes are involved in fusogenic activity?
Key genes include MYMX (Myomixer), FGFRL1, and viral fusion proteins such as the SARS-CoV-2 spike. Other genes like DYSF, MYOF, and SNARE proteins also contribute to membrane fusion.
What diseases are associated with defective fusogenic activity?
Defective fusogenic activity is linked to Carey-Fineman-Ziter syndrome-like myopathy, neuromuscular disorders with satellite cell dysfunction, and impaired viral entry.
How is fusogenic activity measured?
It is measured using lipid-mixing and content-mixing assays, live-cell imaging of syncytium formation, and biochemical assays such as liposome co-flotation.
What is the role of Myomixer in fusogenic activity?
Myomixer is a micropeptide essential for myoblast fusion; its fusogenic activity is required for muscle development, and mutations cause myopathy.
Can fusogenic activity be targeted for drug delivery?
Yes, fusogenic liposomes and nanoparticles exploit this activity to enhance delivery of antimicrobials and anti-inflammatory drugs.
What is the difference between fusogenic activity and membrane fusion?
Fusogenic activity is the molecular function that catalyzes membrane fusion; membrane fusion is the resulting biological process.
Which viruses use fusogenic activity?
Enveloped viruses such as SARS-CoV-2, HCV, and influenza use fusogenic activity of their surface proteins to enter host cells.
How do CRISPR screens help study fusogenic activity?
CRISPR knockout screens can identify genes required for membrane fusion, revealing novel regulators and potential drug targets.
What model systems are used to study fusogenic activity?
Common models include C2C12 myoblasts, HEK293T cells expressing viral fusion proteins, and liposome-based in vitro systems.
Conclusion
Fusogenic activity (GO:0140522) is a fundamental molecular function that drives membrane merger in diverse biological contexts, from viral infection to muscle development. Its dysregulation is linked to human diseases such as Carey-Fineman-Ziter syndrome-like myopathy and neuromuscular disorders, while its exploitation holds promise for drug delivery and antimicrobial therapy. Continued research using CRISPR models, advanced imaging, and biochemical assays will further illuminate the mechanisms and therapeutic potential of fusogenic activity.
References
- 1. Ramirez-Martinez A et al.. 2022. Impaired activity of the fusogenic micropeptide Myomixer causes myopathy resembling Carey-Fineman-Ziter syndrome.. J Clin Invest 132(11) PMID: 35642635
- 2. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 3. Zhuang L et al.. 2017. Evolution of the fusogenic activity of the receptor FGFRL1.. Arch Biochem Biophys 625-626:54-64 PMID: 28596102
- 4. Scriboni AB et al.. 2019. Fusogenic Liposomes Increase the Antimicrobial Activity of Vancomycin Against Staphylococcus aureus Biofilm.. Front Pharmacol 10:1401 PMID: 31849660
- 5. Planas D et al.. 2024. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.. Nat Commun 15(1):2254 PMID: 38480689
- 6. Kim JY et al.. 2024. Hybrid Nanoparticle Engineered with Transforming Growth Factor -β1-Overexpressed Extracellular Vesicle and Cartilage-Targeted Anti-Inflammatory Liposome for Osteoarthritis.. ACS Nano 18(50):33937-33952 PMID: 39648484
- 7. Gonzalez S et al.. 2019. Studies of membranotropic and fusogenic activity of two putative HCV fusion peptides.. Biochim Biophys Acta Biomembr 1861(1):50-61 PMID: 30343120
- 8. Makowski M et al.. 2025. Lipid Shape as a Membrane Activity Modulator of a Fusogenic Antimicrobial Peptide.. J Chem Inf Model 65(9):4554-4567 PMID: 40110793
